Retinal Vein Occlusion
Stories
-
Merck registers Phase 3 trial of MK-8748 in macular edema after retinal vein occlusion
Merck Sharp & Dohme LLC has posted a new Phase 2/3 study to evaluate intravitreal MK-8748 versus aflibercept in participants with macular edema following retinal vein occlusion. The study plans to enroll 1188 participants and is expected to begin on December 21, 2026.